Cara Therapeutics, Inc. (NASDAQ:CARA) Receives $2.32 Consensus Target Price from Analysts

Cara Therapeutics, Inc. (NASDAQ:CARA) has earned a consensus rating of “Hold” from the six research firms that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $2.32.

Separately, StockNews.com initiated coverage on shares of Cara Therapeutics in a report on Sunday. They set a “sell” rating on the stock.

Cara Therapeutics Stock Performance

Cara Therapeutics stock opened at $0.27 on Wednesday. Cara Therapeutics has a 12 month low of $0.24 and a 12 month high of $1.40. The business’s 50 day simple moving average is $0.30 and its 200 day simple moving average is $0.45. The company has a market cap of $14.71 million, a price-to-earnings ratio of -0.12 and a beta of 0.70.

Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. As a group, equities research analysts forecast that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN lifted its position in Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,935,718 shares of the biopharmaceutical company’s stock after purchasing an additional 120,660 shares during the quarter. Disciplined Growth Investors Inc. MN owned about 3.54% of Cara Therapeutics worth $499,000 at the end of the most recent quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.